

To the members of the Arbeitsgemeinschaft Dermatologische Forschung (ADF)

Program of the AG Experimental Dermato-Oncology 2023

Thursday 23.2.23, 9:00-12:30 / CCB Innsbruck, Room L.EG.220

9:00 Welcome Address

Evelyn Gaffal & Alpaslan Tasdogan (Magdeburg, Essen)

9:05-9:20 HLA class II haplotype loss in melanoma and its association with patient resistance to immune checkpoint blockade“

F. Zhao, P. Crivello, M. Laudage, S. Kwapik, A. Heinold, T. Arrieta-Bolanos, A. Sucker, P. Horn, D. Schadendorf, K. Fleischhauer, A. Paschen (Essen)

9:20-9:35 Tumour-specific CD4+ T cells recruit inflammatory monocytes that acquire IFN-activated functions to control immune evasive tumours

A. Buzzai, B. Kruse, N. Shridhar, A. Braun, S. Gellert, K. Knauth, J. Peters, M. Mengoni, T. van der Sluis, A. Krone, D. Yu, S. Hoehn, Y. Fu, M. Essand, R. Geffers, D. Mougiakakos, S. Kahlfuss, H. Kashkar, E. Gaffal, W. Kastenmueller, A. Mueller, T. Tueting (Magdeburg, Uppsala, Braunschweig, Cologne, Wuerzburg)

9:35-9:50 Combination of PARP inhibitors and MAPK inhibitors as an effective treatment strategy for malignant melanoma

L. Froehlich, H. Niessner, T. Sinnberg, B. Schitteck (Tübingen, Berlin)

9:50-10:20 Alterations in dendritic cells by tumor-targeted therapy

F. Hornsteiner, H. Strandt, C.H. Tripp, J. Vierthaler, S. Dieckmann, A. Seretis, M.M. Sykora, N. Kleiter, S. Bregar, S. Sopper, P. Stoitzner (Innsbruck)

10:20-10:50 Coffee break

10:40-10:55 Lyve-1 deficiency enhances the hepatic immune microenvironment entailing altered susceptibility to liver metastasis

S. Wohlfeil, A. Jauch, B. Dietsch, C. Weller, A. Stojanovic, M. Kittel, H. Nolte, A. Cerwenka, M. Neumaier, K. Schledzewski, C. Sticht, P. Reiners-Koch, S. Goerd, C. Géraud (Mannheim, Heidelberg, Cologne)

10:55-11:10 Resistance to BRAF inhibitors: EZH2 and its downstream target PLK1 as potential therapeutic options in melanoma

A. Uebel, K. Gebhardt, S. Kewitz-Hempel, C. Sunderkoetter, D. Gerloff (Halle)

11:10-11:25 Overcoming immune checkpoint inhibitor resistance to improve melanoma therapy

S. Daignault-Mill, D. Moi, B. Zeng, R. Bhatt, R. Ju, L. Griffiths, M. Haritopoulou-Sinanidou, L. Spoerri, R. Dolcetti, N. Haass (Woolloongabba)

11:25-11:55 NLRC5: Fine-tuner of MHC expression and driver of immune evasion in melanoma

Nicole Glodde (Bonn)